Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2017
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors sanofi pasteur
- 21 Aug 2017 Planned End Date changed from 1 Dec 2018 to 21 Feb 2019.
- 21 Aug 2017 Planned primary completion date changed from 1 Sep 2018 to 21 Feb 2019.
- 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.